Jensen Alexandra D, Uhl Matthias, Chaudhri Naved, Herfarth Klaus K, Debus Juergen, Roeder Falk
Department of Radiation Oncology, University of Heidelberg, INF 400, 69120, Heidelberg, Germany.
Department of Medical Physics, Heidelberg Ion Beam Therapy Centre (HIT), Heidelberg, Germany.
Radiat Oncol. 2015 May 6;10:109. doi: 10.1186/s13014-015-0414-8.
To report our early experience with carbon ion irradiation in the treatment of gross residual or unresectable malignant peripheral nerve sheath tumors (MPNST).
We retrospectively analysed 11 patients (pts) with MPNST, who have been treated with carbon ion irradiation (C12) at our institution between 2010 and 2013. All pts had measurable gross disease at the initiation of radiation treatment. Median age was 47 years (29-79). Tumors were mainly located in the pelvic/sacral (5 pts) and sinunasal/orbital region (5 pts). 5 pts presented already in recurrent situation, 3 pts had been previously irradiated, and in 3 pts MPNST were neurofibromatosis type 1 (NF1) associated. Median cumulative dose was 60 GyE. Treatment was carried out either as a combination of IMRT plus C12 boost (4 pts) or C12 only (7 pts).
Median follow-up was 17 months (3-31 months). We observed 3 local progressions, translating into estimated 1- and 2-year local control rates of 65%. One patient developed distant failure, resulting in estimated 1- and 2-year PFS rates of 56%. Two patients have died, therefore the estimated 1- and 2-year OS rates are 75%. Acute radiation related toxicities were generally mild, no grade 3 side effects were observed. Severe late toxicity (grade 3) was scored in 2 patients (trismus, wound healing delays).
Carbon ion irradiation yields very promising short term local control and overall survival rates with low morbidity in patients suffering from gross residual or unresectable malignant peripheral nerve sheath tumors and should be further investigated in a prospective trial.
报告我们在碳离子照射治疗大体残留或不可切除的恶性外周神经鞘瘤(MPNST)方面的早期经验。
我们回顾性分析了2010年至2013年间在本机构接受碳离子照射(C12)治疗的11例MPNST患者。所有患者在放疗开始时均有可测量的大体疾病。中位年龄为47岁(29 - 79岁)。肿瘤主要位于盆腔/骶骨(5例)和鼻窦/眼眶区域(5例)。5例患者为复发状态,3例患者曾接受过放疗,3例MPNST与1型神经纤维瘤病(NF1)相关。中位累积剂量为60 GyE。治疗采用调强适形放疗(IMRT)加C12增敏(4例)或仅C12(7例)的联合方式。
中位随访时间为17个月(3 - 31个月)。我们观察到3例局部进展,1年和2年局部控制率估计为65%。1例患者出现远处转移,1年和2年无进展生存率估计为56%。2例患者死亡,因此1年和2年总生存率估计为75%。急性放射性毒性一般较轻,未观察到3级副作用。2例患者出现严重晚期毒性(3级)(牙关紧闭、伤口愈合延迟)。
碳离子照射在大体残留或不可切除的恶性外周神经鞘瘤患者中产生了非常有前景的短期局部控制率和总生存率,且发病率低,应在前瞻性试验中进一步研究。